Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Has Average Target Price of $11.33

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been assigned an average rating of “Buy” from the nine brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $11.00.

A number of analysts recently commented on the company. Craig Hallum set a $9.00 price target on Aclaris Therapeutics in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. Canaccord Genuity Group began coverage on Aclaris Therapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $10.00 target price for the company. Wall Street Zen upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research note on Wednesday.

Institutional Trading of Aclaris Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Aclaris Therapeutics in the second quarter valued at about $53,096,000. Kalehua Capital Management LLC purchased a new stake in shares of Aclaris Therapeutics during the 1st quarter worth approximately $6,871,000. Palo Alto Investors LP purchased a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth approximately $8,535,045. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth approximately $6,400,000. Finally, Deutsche Bank AG bought a new stake in shares of Aclaris Therapeutics in the 2nd quarter worth approximately $5,507,000. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS opened at $3.99 on Friday. The firm has a market cap of $557.90 million, a price-to-earnings ratio of -6.88 and a beta of 0.87. Aclaris Therapeutics has a 52 week low of $2.10 and a 52 week high of $6.60. The firm has a 50-day moving average price of $4.93 and a two-hundred day moving average price of $4.51.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The firm had revenue of $1.63 million for the quarter, compared to the consensus estimate of $1.38 million. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%. As a group, sell-side analysts forecast that Aclaris Therapeutics will post -0.62 earnings per share for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.